- Home
- CAPR vs USCB Comparison
CAPR vs USCB Comparison
Compare CAPR & USCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- USCB
- Stock Information
- Founded
- CAPR 2005
- USCB 2002
- Country
- CAPR United States
- USCB United States
- Employees
- CAPR N/A
- USCB N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- USCB Major Banks
- Sector
- CAPR Health Care
- USCB Finance
- Exchange
- CAPR Nasdaq
- USCB Nasdaq
- Market Cap
- CAPR 324.6M
- USCB 316.4M
- IPO Year
- CAPR N/A
- USCB 2021
- Fundamental
- Price
- CAPR $6.28
- USCB $17.34
- Analyst Decision
- CAPR Strong Buy
- USCB Buy
- Analyst Count
- CAPR 8
- USCB 3
- Target Price
- CAPR $24.75
- USCB $20.33
- AVG Volume (30 Days)
- CAPR 1.4M
- USCB 16.8K
- Earning Date
- CAPR 08-11-2025
- USCB 07-24-2025
- Dividend Yield
- CAPR N/A
- USCB 2.30%
- EPS Growth
- CAPR N/A
- USCB 67.08
- EPS
- CAPR N/A
- USCB 1.47
- Revenue
- CAPR $13,392,150.00
- USCB $88,094,000.00
- Revenue This Year
- CAPR N/A
- USCB $26.38
- Revenue Next Year
- CAPR $6,061.53
- USCB $4.39
- P/E Ratio
- CAPR N/A
- USCB $11.83
- Revenue Growth
- CAPR N/A
- USCB 32.06
- 52 Week Low
- CAPR $3.98
- USCB $13.85
- 52 Week High
- CAPR $23.40
- USCB $21.86
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- USCB 55.15
- Support Level
- CAPR $6.17
- USCB $17.10
- Resistance Level
- CAPR $7.30
- USCB $17.98
- Average True Range (ATR)
- CAPR 0.43
- USCB 0.52
- MACD
- CAPR -0.11
- USCB 0.06
- Stochastic Oscillator
- CAPR 4.53
- USCB 73.38
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.